Molecular Targets for the Treatment of Metastatic Colorectal Cancer

Cancers

Romain Cohen¹  Thierry André¹  Thomas Pudlarz¹  Jean-François Delattre¹  Raphaël Colle¹ 

[1] Department of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, France;

关键词: colorectal cancer;    NTRK;    HER2;    BRAF;    microsatellite instability;    ctDNA;   

DOI  :  10.3390/cancers12092350

来源: DOAJ

【 摘 要 】

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification or NTRK fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, HER2, NTRK).

【 授权许可】

Unknown